keyword
MENU ▼
Read by QxMD icon Read
search

IBS-C

keyword
https://www.readbyqxmd.com/read/29333891/therapeutic-potential-of-zataria-multiflora-boiss-in-treatment-of-irritable-bowel-syndrome-ibs
#1
Mohaddese Mahboubi
Irritable Bowel syndrome (IBS), the most common chronic functional gastrointestinal disorder, is categorized as IBS-C and IBS-D, which are equivalent to Ghoolenj Rihi and Maghs Rihi in Iranian traditional medicine. One of the main applications of Zataria multiflora Boiss in traditional medicine is its efficacy in the gastrointestinal tract with symptoms such as IBS. The aim of this study was to evaluate the efficacy of Zataria multiflora essential oil in management of IBS. We used all the accessible references (electronic and published books, theses, and reports) to write this article...
January 15, 2018: Journal of Dietary Supplements
https://www.readbyqxmd.com/read/29327820/gastroenterology-today-between-certainties-and-news-a-meeting-held-in-turin-on-may-27-2017
#2
Rinaldo Pellicano, Davide G Ribaldone, Marco Astegiano, Luca Dughera, Edda Battaglia, Anna Morgando, Arrigo Arrigoni, Mauro Spandre, Mario Grassini, Giorgio M Saracco, Francis Mégraud
This special article reports on two crucial issues discussed during a meeting. The first was the updated management of Helicobacter pylori infection. This was approached taking into account the recent European Guidelines, with a focus on novelties in treatment. In particular, considering the increasing H. pylori antibiotic resistance to clarithromycin, in countries with a high clarithromycin resistance rate the bismuth-containing quadruple therapies should be preferred. The new formulation, with bismuth, metronidazole, and tetracycline contained in a single capsule (three-in-one), has shown exciting results both in naive and in non-responder patients...
January 10, 2018: Minerva Gastroenterologica e Dietologica
https://www.readbyqxmd.com/read/29319191/linaclotide-in-irritable-bowel-syndrome-with-constipation-a-phase-3-randomized-trial-in-china-and-other-regions
#3
Yunsheng Yang, Jingyuan Fang, Xiaozhong Guo, Ning Dai, Xizhong Shen, Youlin Yang, Jing Sun, Bal Raj Bhandari, David S Reasner, Jacquelyn A Cronin, Mark G Currie, Jeffrey M Johnston, Peter Zeng, Niwat Montreewasuwat, George Zhijian Chen, Sam Lim
BACKGROUND AND AIM: Linaclotide is a guanylate cyclase-C agonist approved in multiple countries to treat irritable bowel syndrome with constipation (IBS-C). China has unmet need for well-tolerated therapy that is effective in treating both bowel and abdominal symptoms of IBS-C. This trial evaluated linaclotide's efficacy and safety in IBS-C patients in China and other regions. METHODS: This Phase 3, double-blind trial randomized IBS-C patients to once-daily oral 290-μg linaclotide or placebo at centers in China, North America, and Oceania...
January 10, 2018: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29284389/efficacy-and-safety-of-serotonin-receptor-ligands-in-the-treatment-of-irritable-bowel-syndrome-a-review
#4
Agata Binienda, Martin Storr, Jakub Fichna, Maciej Salaga
Irritable bowel syndrome (IBS) is a chronic, recurrent bowel disorder with an unknown etiology, which is most likely multifactorial. Increased mucosal permeability, visceral hypersensitivity and activation status of intestinal mucosal immune cells cause changes in gastrointestinal (GI) motility, secretion and sensation observed in the course of IBS. Permanent, cumbersome symptoms, such as diarrhea, constipation and abdominal pain greatly lower quality of life of IBS patients. On this basis, according to the Rome IV criteria, different forms of IBS can be distinguished...
December 27, 2017: Current Drug Targets
https://www.readbyqxmd.com/read/29278278/determining-an-optimal-dose-of-linaclotide-for-use-in-japanese-patients-with-irritable-bowel-syndrome-with-constipation-a-phase-ii-randomized-double-blind-placebo-controlled-study
#5
S Fukudo, A Nakajima, Y Fujiyama, M Kosako, A Nakagawa, H Akiho, Y Nakashima, J M Johnston, H Miwa
BACKGROUND: Clinical testing to determine a suitable dose of linaclotide for Japanese patients with irritable bowel syndrome with constipation (IBS-C) was needed. METHODS: This was a randomized, double-blind, placebo-controlled, dose-finding trial. Japanese patients with IBS-C diagnosed using Rome III criteria (n = 559, men/women: 49/510) were randomly assigned to 1 of 4 linaclotide doses (0.0625, 0.125, 0.25, or 0.5 mg) or placebo for the 12-week treatment period...
December 26, 2017: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
https://www.readbyqxmd.com/read/29184433/diagnosis-and-treatment-of-irritable-bowel-syndrome-with-predominant-constipation-in-the-primary-care-setting-focus-on-linaclotide
#6
REVIEW
Apoorva Krishna Chandar
Irritable bowel syndrome (IBS) is a complex functional gastrointestinal disorder that is exceedingly common in clinical practice. IBS with predominant constipation (IBS-C) is a subtype of IBS that accounts for more than a third of the IBS diagnosed. Diagnosis of IBS requires a careful personalized approach, a comprehensive clinical history, limited but relevant investigations, and continued follow-up. Major IBS societies and guidelines recommend offering a positive diagnosis of IBS based on presenting symptomatology...
2017: International Journal of General Medicine
https://www.readbyqxmd.com/read/29155167/bile-acids-and-bowel-function-do-they-play-a-role-in-ibs-c
#7
EDITORIAL
Arnold Wald
No abstract text is available yet for this article.
November 15, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29027719/glioplasticity-in-irritable-bowel-syndrome
#8
N L Lilli, L Quénéhervé, S Haddara, C Brochard, P Aubert, M Rolli-Derkinderen, T Durand, P Naveilhan, J-B Hardouin, R De Giorgio, G Barbara, S Bruley des Varannes, E Coron, M Neunlist
BACKGROUND: Growing evidence indicates a wide array of cellular remodeling in the mucosal microenvironment during irritable bowel syndrome (IBS), which possibly contributes to pathophysiology and symptom generation. Here, we investigated whether enteric glial cells (EGC) may be altered, and which factors/mechanisms lead to these changes. METHODS: Colonic mucosal biopsies of IBS patients (13 IBS-Constipation [IBS-C]; 10 IBS-Diarrhea [IBS-D]; 11 IBS-Mixed [IBS-M]) and 24 healthy controls (HC) were analyzed...
October 13, 2017: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
https://www.readbyqxmd.com/read/28992677/nationwide-multicenter-study-for-overlaps-of-common-functional-gastrointestinal-disorders-in-korean-patients-with-constipation
#9
Kyung Sik Park, Sam Ryong Jee, Bong Eun Lee, Kyoung Sup Hong, Jeong Eun Shin, Soo-Young Na, Joong Goo Kwon, Suck Chei Choi, Yong Sung Kim, Hyun Seok Lee, Tae Hee Lee, Kyeong Ok Kim, Jongkyoung Choi, Hee Seok Moon, Yeon Soo Kim, Moo In Park, Soo Jung Park, Seon-Young Park, Sung Noh Hong
Background/Aims: In spite of increased concerns about the overlaps among the various functional gastrointestinal disorders (FGIDs), studies for the overlap between constipation and other common FGIDs are rare. Therefore, we investigated the patterns of overlaps between constipation and other common FGIDs. Methods: This study was designed as a prospective nationwide multi-center questionnaire study using Rome III questionnaires for functional dyspepsia (FD), irritable bowel syndrome (IBS), and functional constipation (FC), as well as various questionnaires about patients' information, degree of symptoms, and quality of life...
October 30, 2017: Journal of Neurogastroenterology and Motility
https://www.readbyqxmd.com/read/28989013/development-of-a-modified-release-formulation-of-lovastatin-targeted-to-intestinal-methanogens-implicated-in-irritable-bowel-syndrome-with-constipation
#10
Steven Hubert, Alan Chadwick, Vince Wacher, Olivia Coughlin, John Kokai-Kun, Andrew Bristol
There is growing evidence that methane production, predominantly by Methanobrevibacter smithii, in the intestines is a cause of constipation, pain, and bloating in irritable bowel syndrome with constipation (IBS-C). M smithii resides primarily in the large intestine but can also colonize the small intestine. In vitro studies found that the prodrug lactone form of lovastatin, found in cholesterol-lowering drugs, inhibited methane production in stool samples from patients with IBS-C. However, the cholesterol-lowering lovastatin β-hydroxyacid was ineffective at inhibiting methane production in this system...
October 6, 2017: Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28975689/inflammatory-cell-distribution-in-colon-mucosa-as-a-new-tool-for-diagnosis-of-irritable-bowel-syndrome-a-promising-pilot-study
#11
J Boyer, M-C Saint-Paul, B Dadone, S Patouraux, M-H Vivinus, D Ouvrier, J-F Michiels, T Piche, M K Tulic
BACKGROUND: Currently, there are no histological criteria to diagnose irritable bowel syndrome (IBS). Our aims were (i) to examine the distribution of inflammatory cells in the colon of healthy and IBS subjects and (ii) to find histological diagnosis criteria for IBS. METHODS: Colonic biopsies were taken from four distinct regions of the colon from 20 controls (HC) and 11 patients with IBS (4 with constipation (IBS-C) and 7 with diarrhea (IBS-D) and embedded in paraffin...
January 2018: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
https://www.readbyqxmd.com/read/28886490/interleukin-6-in-irritable-bowel-syndrome-a-systematic-review-and-meta-analysis-of-il-6-g174c-and-circulating-il-6-levels
#12
REVIEW
Mohammad Bashashati, Maryam Moradi, Irene Sarosiek
BACKGROUND: Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder which presents with abdominal pain and alterations of the bowel habits. The pathophysiology of IBS is not well-recognized. Low grade inflammation has been suggested as one of the underlying mechanisms of IBS. Variations in the circulating pro-inflammatory interleukin-6 (IL-6) levels and IL-6 gene polymorphisms have been demonstrated in IBS. However, the results of published studies are not consistent, probably due to their small sample sizes...
September 5, 2017: Cytokine
https://www.readbyqxmd.com/read/28809383/increasing-symptoms-in-irritable-bowel-symptoms-with-ingestion-of-galacto-oligosaccharides-are-mitigated-by-%C3%AE-galactosidase-treatment
#13
C J Tuck, K M Taylor, P R Gibson, J S Barrett, J G Muir
OBJECTIVES: Galacto-oligosaccharides (GOS) are dietary FODMAPs (fermentable carbohydrates) associated with triggering gastrointestinal symptoms in patients with irritable bowel syndrome (IBS). This randomized, double-blind, placebo-controlled, cross-over trial aimed to assess whether oral α-galactosidase co-ingestion with foods high in GOS and low in other FODMAPs would reduce symptoms. METHODS: Patients meeting the Rome III criteria for IBS who were hydrogen-producers on breath testing were recruited...
August 15, 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28808081/%C3%A2-eluxadoline-for-ibs-d
#14
(no author information available yet)
Irritable bowel syndrome (IBS) is a chronic relapsing gastrointestinal problem characterised by intestinal pain and associated alterations of defecation and/or bowel habit (constipation: IBS-C or diarrhoea: IBS-D).(1,2) Opioid receptors in the gut have a role in gastrointestinal motility, secretion and sensation.(3) Τ Eluxadoline (Truberzi-Allergan) is a locally acting, mixed opioid receptor agonist/antagonist licensed for the treatment of IBS-D in adults.(4) Here, we consider the evidence for eluxadoline and how it fts with current management strategies for IBS-D...
August 2017: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/28799291/inaccuracy-of-patient-reported-descriptions-of-and-satisfaction-with-bowel-actions-in-irritable-bowel-syndrome
#15
E P Halmos, J R Biesiekierski, E D Newnham, R E Burgell, J G Muir, P R Gibson
BACKGROUND: Perception of diarrhea and constipation differs greatly. This study aimed to correlate subjective and objective assessment of fecal characteristics in irritable bowel syndrome (IBS) patients. METHODS: Data from two interventional dietary trials with varying FODMAP (Fermentable Oligosaccharides, Disaccharides, Monosaccharides And Polyols) or gluten content were interrogated. Subjects rated their dissatisfaction with stool consistency daily using a visual analog scale during the interventions...
August 10, 2017: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
https://www.readbyqxmd.com/read/28774781/estrogen-signaling-deregulation-related-with-local-immune-response-modulation-in-irritable-bowel-syndrome
#16
REVIEW
Damian Jacenik, Adam I Cygankiewicz, Jakub Fichna, Anna Mokrowiecka, Ewa Małecka-Panas, Wanda M Krajewska
The etiology and pathogenesis underlying irritable bowel syndrome (IBS), a common gastrointestinal disorder are still unclear. Cumulating data suggest dysregulation of inflammatory and immune response pathways and changes of epithelial barrier function. The role of estrogens albeit varied, in responses of immune system is well documented. The aim of this study was to investigate estrogen receptors engagment in IBS subtypes, i.e. constipation predominant (IBS-C) and diarrhea predominant (IBS-D). Furthermore, we analyzed whether estrogen signaling is accompanied by alteration in expression of pro- and anti-inflammatory cytokines and microRNAs that can regulate among others genes involved in immune responses...
July 31, 2017: Molecular and Cellular Endocrinology
https://www.readbyqxmd.com/read/28764761/abnormalities-in-ileal-stem-neurogenin-3-and-enteroendocrine-cells-in-patients-with-irritable-bowel-syndrome
#17
Magdy El-Salhy, Odd Helge Gilja
BACKGROUND: This study examined whether the densities of stem- and enteroendocrine cell progenitors are abnormal in the ileum of patients with irritable bowel syndrome (IBS), and whether any abnormalities in ileal enteroendocrine cells are correlated with abnormalities in stem cells and enteroendocrine cell progenitors. METHODS: One hundred and one IBS patients covering all IBS subtypes were recruited, and 39 non-IBS subjects were included as a control group. The patients and controls underwent standard colonoscopies, during which biopsy specimens were obtained from the ileum...
August 1, 2017: BMC Gastroenterology
https://www.readbyqxmd.com/read/28757466/identification-of-serum-proteome-signature-of-irritable-bowel-syndrome-potential-utility-of-the-tool-for-early-diagnosis-and-patient-s-stratification
#18
Athanasios Tsigaridas, Athanassios K Anagnostopoulos, Aggeliki Papadopoulou, Stamatia Ioakeim, Anna Vaiopoulou, Ioannis S Papanikolaou, Nikos Viazis, George Karamanolis, Gerasimos J Mantzaris, George T Tsangaris, Maria Gazouli
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder with high incidence, and great heterogeneity of symptoms. Numerous factors are correlated with IBS development; however, the pathophysiology is not yet clear. In addition, there is no appropriate diagnostic tool available. The aim of this study was the identification of protein expression alterations in IBS patients compared to healthy individuals. Serum samples from 30 IBS patients (10 with IBS-Diarrhea, 10 IBS-Constipation and 10 IBS-Mixed) and 10 healthy individuals were subjected to proteomic analysis by 2-dimensional gel electrophoresis...
July 28, 2017: Journal of Proteomics
https://www.readbyqxmd.com/read/28666948/bile-acid-deficiency-in-a-subgroup-of-patients-with-irritable-bowel-syndrome-with-constipation-based-on-biomarkers-in-serum-and-fecal-samples
#19
Priya Vijayvargiya, Irene Busciglio, Duane Burton, Leslie Donato, Alan Lueke, Michael Camilleri
BACKGROUND & AIMS: Short-term administration of delayed-release chenodeoxycholic acid to patients with irritable bowel syndrome with constipation (IBS-C) accelerates colonic transit and reduces symptoms. A preliminary study has shown that patients with IBS-C have reduced levels of bile acids (BAs) in feces and reduced synthesis of BA. We compared the levels of primary and secondary BAs in fecal samples collected over a 48-hour period from patients with IBS-C on a diet that contained 100 g fat per day, and compared them with levels in samples from healthy volunteers (controls)...
June 27, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28643273/chronic-constipation-in-rome-iv-era-the-indian-perspective
#20
REVIEW
Uday C Ghoshal
Chronic constipation (CC) is a common problem in the community and in gastroenterology practice all over the world including India. After release of Rome IV guidelines in April 2016, there is increasing interest among gastroenterologists and physicians in India to look into special issues on CC in the Indian perspective. There are important differences in the bowel habit, definition, epidemiology, and pathophysiology including dietary factors and management of CC in India as compared to the West. As severity and frequency of abdominal pain, a symptom essential to diagnose constipation-predominant irritable bowel syndrome (IBS-C) rather than functional constipation (FC), is less common among Indian patients, FC is commoner than IBS-C in India...
May 2017: Indian Journal of Gastroenterology: Official Journal of the Indian Society of Gastroenterology
keyword
keyword
89761
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"